Aside from the tiny minority of people who can actually say what each of those initials stand for, we can divide the populace into two groups – those who specifically know that CRISPR is a tool used in gene editing and those who know (or figure) that it’s a highly promising but exceedingly complex technique […]
Articles
Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same. Happily, thinking about migraines will not give me COVID-19. But migraines are by no means a topic of no consequence, […]
Mostly in these Doc Gumshoe pieces I try to keep my focus on what the physicians and researchers and pharmaceutical outfits are doing to try to treat, or at least manage, all these diseases, ailments, and conditions that affect our lives. But other issues keep thrusting themselves into the picture, especially the cost factor. […]
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. My impressions and conclusions are in some cases only loosely based on […]
The answer to that foolish question is certainly going to be “both.” But the finger pointing at the guilty party has wobbled around a good deal in the past few years, and just before Christmas, the American Heart Association came out with a set of dietary recommendations once again apparently putting at least some blame […]
“CRISPR” is the word in the headline that signals that the piece is going to be about gene editing. Doc Gumshoe did not want to put that word – actually, it’s not really a word, but an acronym – in the title of this piece because gene editing is a whole lot more than […]
This article was originally published on March 21, 2019 when the “deadline” touted was March 25. We’ve lightly updated our piece below, but much of it (like the ad) is unchanged from March. The latest ad for Green Chip Stocks is a doozy — reminiscent of the many “the world is about to change” ads […]
When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course, that the mother of Achilles dipped him in the River Styx when he was a tiny boy, […]
Since I added to a telecom/5G stock today, and I see that same stock being teased again this week, I thought I’d take this Friday opportunity to solve a teaser for you as I update you on my portfolio moves. The teaser is from Michael Robinson for his Nova-X Report ($79/year), and it sounds kind […]
Chances are not many of us observed New Year’s Eve with celebratory toasts to the glorious year gone by. Rather, we bid goodbye to 2018 and hoped 2019 would be a better year – for ourselves, our near and dear, our country, and our planet. However, as I wade through the volumes of healthcare-related stuff […]
Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.” I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]
Hello, dear friends — I have a few portfolio updates to start with as I get you updated on a few trades that triggered since I last wrote, so adjustments to the portfolio (including a few buys and sells) will be the focus of today’s Friday File. The latest update to the Real Money Portfolio […]
Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]
No, these bits won’t be about Melania’s kidney ailment nor yet about what Meghan wore for The Wedding. I wish them both luck – they’ll need it!. However, there continue to be developments on the medical and health-care fronts that may matter to us a good deal more than the doings of those ladies. […]
Gumshoe readers wanna know: What’s a “Liberty Voucher?” And you can see why — inspired by the success of the ads that tease us about “Freedom Checks” or “Trump Bonus Checks”, this one from Nilus Mattive is all about getting your attention with the idea that those who don’t have enough cash flow to retire […]
We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He’s agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see his past articles and most recent comments here.] The death of Mr. Chiang, who was always kind, has never set well […]
Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Ho ho ho! And Happy Christmas to all […]
[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
10/28 update: this article is about a week old, but the teaser ads have changed a bit — the newsletter is now also being pitched under the headline, “Has this Maine town bottled the fountain of youth?” and it’s now also going out under the name Dr. Richard Robinson, who apparently works on the newsletter […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes non-investment articles for us about medical and health topics a couple times a month. He is a medical writer, not a doctor, and his words and thoughts are his own.] Just possibly a tiny few of the Gumshoe faithful may remember that advertising […]
Pain management is a huge market in the medical world, as you’re no doubt aware — and buckets of money are pouring down on the many, many little biotech stocks who are trying to develop new pain medications, or to tweak existing medications to make them safer or less likely to be abused. So it’s […]
[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
February 27, 2015 /
Michael Jorrin, "Doc Gumshoe"
Celiac Disease and the Ubiquitous Gluten-Free Diet
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with our readers a couple times a month. He does not generally cover investing topics, but I find his discussions of broader health issues interesting and useful. Enjoy!] Doc Gumshoe would not be […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]
[Michael Jorrin, who we like to call “Doc Gumshoe”, is a medical writer who shares his thoughts with us once or twice a month. He does not usually recommend or discuss investments, and, as with all of our contributors, his words are his own and he chooses his own topics.] To start us off, three […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. His topics, words and opinions are his own. Enjoy!] It’s the second reel of conspiracy film Shooter, and Mark Wahlberg, whom government schemers are trying to frame for assassination, has just been shot twice. In the back of a stolen FBI car, […]
[ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
What’s the commonest reason for admission to hospital of people 65 and over? Mull that question, as it provides context. Think of people you know. At least one probably has this condition. It’s not diabetes. It’s not heart attacks. And it is not infectious. But it kills and lots of people have it. Part II […]
[Ed. Note: Dr. KSS, formerly knowns as karmaswimswami on our discussion threads, is here again to talk to the Irregulars about health and medicine and biotech investing ideas. As with all of our guest contributors, he has agreed to our trading restrictions and we have not reviewed, approved or screened his stocks or ideas, and […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
As promised, we’re following up with the rest of the picks that Stephen Leeb (sorry, Dr. Stephen Leeb) is pitching as his “MCR” Plan. If you missed our first entry as we began demystifying this particular ad, you can see it here — the short version is, he’s touting dividend paying stocks in the medical […]
Here we have another email ad for the Skousen Hedge Fund Trader, which has steered us toward both good and bad ideas lately (at least, good or bad if we’re looking at short term performance — which isn’t necessarily what Skousen is aiming for). This one sounds pretty appealing when we have markets moving like […]
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I owned Novartis (NVS) last year and did ok, but I got hit by a small foreign tax withholding, even in my IRA account. J...
Lubris BioPharma - Novartis $NVS - While searching this morning I found this article via Yahoo Finance: "Lubris BioPharm...
Serelaxin has failed in phase 3 for Novartis $NVS, a major blow to the company and to the field of heart failure managem...
Doc, there is another name that Rodman and Renshaw is also bullish on and you have made both positive and negative comme...
Novartis (NVS) touting 13 blockbuster's. https://endpts.com/fighting-a-generic-onslaught-novartis-adds-car-t-to-its-gr...
Novartis (NVS) in the hunt along with KITE for the first established CAR-T treatment to come to the market.It should be...
Novartis (NVS) thus far doing some impressive work with CTLO19 . https://www.novartis.com/news/media-releases/novarti...
Novartis (NVS) doing a big time new RD structure. http://endpts.com/novartis-unveils-a-new-global-rd-structure-with-n...
$CLCD long. Amgen ($AMGN) and Novartis’ ($NVS) migraine drug erenumab has hit the primary endpoint in a Phase II trial...
CRISPR/Cas9 company Intellia getting set for 140 million IPO with a 75 million partnership intact with Regeneron (REGN) ...
I closed out my position in Novartis $NVS today after several good years. The chart is broken after a sustained bull run...
Novartis (NVS) gets FDA approval of its new heart drug. http://www.forbes.com/sites/johnlamattina/2015/07/08/new-heart-...
$JUNO GOOD NEWS! Juno Investors Applaud End to Patent Fight -- Market Talk Cancer-drug developer JUNO gets a lif...
This Biotech (Aduro) put in for a IPO in March for 86 million and will be highly sought for after this deal with Novarti...
Nice interview about Novartis (NVS) drug LCZ696. http://www.medscape.com/viewarticle/838396?src=wnl_edit_specol Doc Ks...
Good Evening, greetings felllow boarders. Hard at work, you need a little diversion. By error I ended up buying EPR...
Thanks Dr. KSS. A-gain! Will hold off on $PFE, particularly as I keep pondering Novartis $NVS a company that, while valu...
Novartis (NVS) Farydak FDA approved for treatment of multiple mylenoma. http://www.fda.gov/NewsEvents/Newsroom/PressA...
Some "selected intelligence" relevant for several stocks of interest here: (1) Novartis $NVS. While this is a very la...
Glenn: I will have to do a little deeper digging on $IMUC, I am interested in it, but am trying to persuade myself that ...
Companies those working on RNA therapeutics, like Fierce Biotech broke the news that the Swiss giant, Novartis (NVS) was...
What effects (if any) can we expect from this development? Here are the lead paragraphs from the Novaratis announcement...
Does anyone have an opinion on whether LCZ696 has enough potential to seriously move the needle for Novartis (NVS)? The ...